Mr. Pines joined Athyrium in 2008 and currently serves as a Partner. Mr. Pines' expertise lies in sourcing and identifying attractive investment opportunities through his deep network of contacts within the healthcare industry. From sourcing, to negotiating, to structuring, to executing, to monitoring, Mr. Pines has been involved in every stage of the investment process on numerous structured transactions.
Before joining Athyrium, and beginning in 2005, Mr. Pines worked with Mr. Ferrell at Barclays Capital and as part of the Lehman Brothers Global Trading Strategies life sciences team. While at Lehman Brothers, Mr. Pines had substantial involvement in the equity and structured investments life sciences portfolio. Representative structured investments include companies such as Jazz Pharmaceuticals, ISTA Pharmaceuticals, Nektar Therapeutics and Orthovita. Representative equity investments include companies such as Sequenom, Genentech, Incyte Corporation, Acorda Therapeutics, I-trax, Penwest Pharmaceuticals and Kalabios (private).
Prior to Lehman, he was an Analyst in Credit Suisse’s Investment Banking Division focused on healthcare clients. Mr. Pines worked in a traditional healthcare coverage role before moving to a product group called the Buyside Insights Group, which provided strategic insights to the firm’s clients utilizing a value-based framework.
Mr. Pines graduated with a B.S. in both Accounting and Finance from Indiana University in 2001.